Developer docs
API playgroundTry for free, no card

Search company profiles

RareMoon Consulting

Full company profile

uuid0025uwt

Namestring
RareMoon Consulting
Legal namestring
RareMoon Consulting, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

RareMoon Consulting is a private regulatory services firm founded in 2016 that provides specialized regulatory affairs consulting to life science and rare disease companies developing orphan drugs, cell therapies, gene therapies, and other advanced therapeutic products. The firm operates from a Washington D.C. headquarters with international subsidiaries in London (RareMoon Consulting LTD) and Barcelona (RareMoon Consulting ESP S.L), enabling multi-jurisdictional delivery across FDA, EMA, Health Canada, and global health agencies. The company does not develop proprietary technology products; instead, its offering is built on deep human expertise, with a team that includes former FDA reviewers from the Office of Therapeutic Products and a former EMA PDCO PIP expert, supporting sponsors across IND/CTA/NDA/BLA preparation, expedited designation strategy (Orphan Drug, RMAT, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, PRIME), health agency meeting preparation, regulatory publishing, and fractional regulatory leadership engagements.

The company's service portfolio spans fractional regulatory services, gene and cell therapy consulting, regulatory filings and operations, orphan drug designations, regulatory designations, health agency meetings, and publishing/submissions management. As of June 2025, RareMoon reported 250+ FDA and EMA Orphan Drug Designations secured, 100+ Rare Pediatric Disease Designations (over 20% of all FDA RPD designations), 40+ Fast Track/Breakthrough/RMAT designations, and 400+ unique assets supported, with a 100% RMAT success rate since supporting the first FDA RMAT ever granted in 2017.

Revenue is generated through professional services engagements (project-based and multi-year fractional leadership contracts) on a quote-based pricing model that is not publicly disclosed. The go-to-market motion is enterprise-focused and event-driven, anchored by 40-50 strategic meetings annually at the J.P. Morgan Healthcare Conference, supplemented by ASGCT Annual Meeting presence, the quarterly IMPACT newsletter, and direct referrals. The firm is bootstrapped and founder-led by co-founders Sabrina Mogle (CEO) and Christopher Novashinski (COO), with no disclosed external institutional investment, no parent company, and no acquisition history to date. In May 2026, RareMoon announced a strategic partnership with Franklin Biolabs to offer integrated preclinical-to-clinical consulting packages.

Short descriptiontext

RareMoon Consulting is a private regulatory services firm that provides orphan drug and advanced therapy regulatory affairs consulting — including FDA/EMA submissions, expedited designations, and fractional regulatory leadership — to biotech and rare disease sponsors, founded in 2016 and headquartered in Washington D.C.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs consulting, orphan drug designations, cell and gene therapy consulting, FDA submission services, regulatory strategy consulting
Industry2 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Other Management Consulting Services541618
  • Other Scientific and Technical Consulting Services54169
  • All Other Professional, Scientific, and Technical Services541990
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Misc Health & Allied Services, Nec8090
Product category
Pharmaceutical Regulatory Affairs Consulting
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Regulatory Consulting Services
TypeProfessional Services
Description

RareMoon generates revenue through professional services engagements including regulatory strategy, FDA/EMA submissions, designation requests (Orphan Drug, RMAT, Breakthrough Therapy), and agency meeting preparation. Services are delivered through fractional regulatory leadership, project-based consulting, and end-to-end regulatory operations support.

raremoonconsulting.com
2Fractional Regulatory Leadership
TypeSubscription Recurring
Description

Provides senior-level regulatory leadership (Fractional Head of Regulatory) to biotech companies without full-time hiring needs. This subscription-style engagement model offers flexible, ongoing regulatory guidance and execution support, backed by a team of multi-disciplinary specialists.

raremoonconsulting.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Operations, Infrastructure, Technology or R&D
Pricing details1 tier
1Quote-based professional services engagement
ModelOtherBilling cadenceMulti-year contract
Notes

No standard pricing tiers published. Services are custom-quoted based on scope, complexity, and engagement type (fractional leadership vs. project-based).

raremoonconsulting.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RareMoon Consulting provides regulatory affairs consulting services for life science and rare disease companies developing orphan drugs and advanced therapies. Its core offerings include fractional regulatory leadership, regulatory strategy, FDA/EMA/global submissions (IND, CTA, NDA, BLA), orphan drug and expedited program designations (RMAT, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, PRIME), health agency meeting support, and end-to-end regulatory operations and publishing. All services are delivered through expert consulting engagements rather than a software platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% RMAT success rate since supporting the first RMAT ever granted by FDA in 2017
+4 more records
Product overview1 text field

RareMoon Consulting is a regulatory services firm offering a comprehensive portfolio of consulting services for life science and rare disease companies. The core offering centers on regulatory affairs expertise for small molecules, biologics, and advanced therapeutic products including cell and gene therapies. Key services include Fractional Regulatory Services (senior regulatory leadership), Gene Therapy Consulting, Regulatory Filings & Operations (IND/CTA/BLA/NDA submissions), Orphan Drug Designations, Regulatory Designations (RMAT, Breakthrough Therapy, Fast Track, PRIME), Health Agency Meetings, and Publishing & Submissions. The firm provides end-to-end support across FDA, EMA, Health Canada, and global health agencies, with specialized expertise in FDA Rare Pediatric Disease designations. RareMoon does not offer a software platform or technology product; all services are delivered through expert consulting engagements.

Product and service7 records
1Fractional Regulatory Services
CategoryRegulatory affairs consulting
Description

Provides senior-level regulatory leadership and real-time regulatory advisement to biotech and pharmaceutical sponsors developing orphan drugs and advanced therapies without the cost of full-time hires.

2Gene Therapy Consulting
CategoryAdvanced therapy regulatory consulting
Description

Regulatory and development strategy for cell and gene therapy programs, including AAV, CAR-T, CRISPR, epigenetic platforms, and other regenerative medicine products.

3Regulatory Filings & Operations
CategoryRegulatory submissions and operations
Description

Strategic preparation and execution of IND, CTA, NDA, BLA, and global regulatory submissions to FDA, EMA, Health Canada, and EU national agencies.

4Orphan Drug Designations
CategoryRegulatory designations
Description

End-to-end support for securing FDA and EMA Orphan Drug Designations, including eligibility assessment, authoring, quality review, and submission management.

5Regulatory Designations
CategoryRegulatory designations
Description

Strategic support for expedited FDA and EMA designations including RMAT, Breakthrough Therapy, Fast Track, Priority Review, Rare Pediatric Disease, and PRIME, including eligibility, authoring, submission, and post-designation planning.

6Health Agency Meetings
CategoryRegulatory agency interactions
Description

End-to-end support for FDA, EMA, Health Canada, and global health agency meetings including INTERACT, Pre-IND, End-of-Phase, and Scientific Advice sessions.

7Publishing & Submissions
CategoryRegulatory operations and publishing
Description

End-to-end regulatory publishing and submission management including eCTD formatting, quality control, regulatory project management, SME applications for EMA, and US Agent/EU Sponsor services.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

RareMoon Consulting and Franklin Biolabs announced a strategic partnership in May 2026 to offer integrated consulting packages supporting preclinical-to-clinical development transitions. Franklin Biolabs is a preclinical contract research organization specializing in genetic medicine and biologics. The collaboration aims to help sponsors design development programs that align with regulatory expectations, reduce development risk, prevent delays, and accelerate timelines by avoiding unnecessary studies. Both companies will discuss the partnership at the ASGCT Annual Meeting in Boston, May 12-14, 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Regulatory, compliance, and medical affairs consulting firm serving pharma, biotech, and medical device clients. Comparable to RareMoon in providing regulatory strategy and submission support, with broader compliance offerings.

TypeBroad incumbent
Description

World's largest CRO with extensive regulatory consulting capabilities spanning small molecules, biologics, and advanced therapies. Represents scale competition to boutique regulatory consultancies like RareMoon.

TypeBroad incumbent
Description

Large global CRO offering regulatory consulting, clinical development, and commercialization services across all therapeutic areas. Represents the broad incumbent alternative to boutique firms like RareMoon, with bundled service offerings.

TypeBroad incumbent
Description

Global regulatory and pharmacovigilance consulting firm now part of Cencora, offering FDA, EMA, and global submission services. Comparable to RareMoon in regulatory strategy with much broader geographic and therapeutic coverage.

TypeDirect peer
Description

Regulatory and HTA consulting firm with strong FDA and EMA capabilities serving pharma and biotech clients. Comparable to RareMoon's transatlantic regulatory practice and orphan drug expertise.

TypeDirect peer
Description

Regulatory and quality consulting firm serving life sciences companies across development phases. Comparable to RareMoon in offering regulatory strategy, submissions support, and quality services to biotech and pharma sponsors.

TypeDirect peer
Description

Regulatory consulting firm specializing in biologics, vaccines, and advanced therapies with deep FDA CBER expertise. Closely comparable to RareMoon's advanced therapy and gene therapy consulting practice.

TypeDirect peer
Description

Regulatory and medical affairs consultancy serving biotech and pharma with expertise across rare disease and advanced therapies. Comparable to RareMoon in regulatory strategy and orphan drug submissions support.

9Camargo Pharmaceutical Services
TypeDirect peer
Description

Specialized regulatory consulting firm with deep orphan drug, 505(b)(2), and complex generics expertise. Highly comparable to RareMoon as a niche consultancy serving small and mid-cap pharma sponsors on regulatory strategy and FDA interactions.

TypeDirect peer
Description

Global regulatory and HTA consulting firm serving biotech and pharma with FDA, EMA, and international submission expertise. Comparable to RareMoon in regulatory strategy and orphan drug focus, with a broader global footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RareMoon Consulting

Pharmaceutical Regulatory Affairs Consultingraremoonconsulting.com

RareMoon Consulting is a private regulatory services firm that provides orphan drug and advanced therapy regulatory affairs consulting — including FDA/EMA submissions, expedited designations, and fractional regulatory leadership — to biotech and rare disease sponsors, founded in 2016 and headquartered in Washington D.C.

What RareMoon Consulting does

RareMoon Consulting is a private regulatory services firm founded in 2016 that provides specialized regulatory affairs consulting to life science and rare disease companies developing orphan drugs, cell therapies, gene therapies, and other advanced therapeutic products. The firm operates from a Washington D.C. headquarters with international subsidiaries in London (RareMoon Consulting LTD) and Barcelona (RareMoon Consulting ESP S.L), enabling multi-jurisdictional delivery across FDA, EMA, Health Canada, and global health agencies. The company does not develop proprietary technology products; instead, its offering is built on deep human expertise, with a team that includes former FDA reviewers from the Office of Therapeutic Products and a former EMA PDCO PIP expert, supporting sponsors across IND/CTA/NDA/BLA preparation, expedited designation strategy (Orphan Drug, RMAT, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, PRIME), health agency meeting preparation, regulatory publishing, and fractional regulatory leadership engagements.

The company's service portfolio spans fractional regulatory services, gene and cell therapy consulting, regulatory filings and operations, orphan drug designations, regulatory designations, health agency meetings, and publishing/submissions management. As of June 2025, RareMoon reported 250+ FDA and EMA Orphan Drug Designations secured, 100+ Rare Pediatric Disease Designations (over 20% of all FDA RPD designations), 40+ Fast Track/Breakthrough/RMAT designations, and 400+ unique assets supported, with a 100% RMAT success rate since supporting the first FDA RMAT ever granted in 2017.

Revenue is generated through professional services engagements (project-based and multi-year fractional leadership contracts) on a quote-based pricing model that is not publicly disclosed. The go-to-market motion is enterprise-focused and event-driven, anchored by 40-50 strategic meetings annually at the J.P. Morgan Healthcare Conference, supplemented by ASGCT Annual Meeting presence, the quarterly IMPACT newsletter, and direct referrals. The firm is bootstrapped and founder-led by co-founders Sabrina Mogle (CEO) and Christopher Novashinski (COO), with no disclosed external institutional investment, no parent company, and no acquisition history to date. In May 2026, RareMoon announced a strategic partnership with Franklin Biolabs to offer integrated preclinical-to-clinical consulting packages.

RareMoon Consulting firmographics

Firmographics
Name
RareMoon Consulting
Legal name
RareMoon Consulting, Inc.
Website
https://raremoonconsulting.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
RareMoon Consulting is a private regulatory services firm that provides orphan drug and advanced therapy regulatory affairs consulting — including FDA/EMA submissions, expedited designations, and fractional regulatory leadership — to biotech and rare disease sponsors, founded in 2016 and headquartered in Washington D.C.
Ownership category
akta.pro rank

RareMoon Consulting industry classification

Industry
Product category
Pharmaceutical Regulatory Affairs Consulting
NAICS
Other Management Consulting Services (541618), Other Scientific and Technical Consulting Services (54169), All Other Professional, Scientific, and Technical Services (541990)
SIC
Services-Management Consulting Services (8742), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Regulatory affairs consulting
  • Orphan drug designations
  • Cell and gene therapy consulting
  • FDA submission services
  • Regulatory strategy consulting

Where RareMoon Consulting is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices3 records

Markets served

RareMoon Consulting business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Marketing or Sales, Operations, Infrastructure, Technology or R&D

Revenue model

  1. Regulatory Consulting Services: RareMoon generates revenue through professional services engagements including regulatory strategy, FDA/EMA submissions, designation requests (Orphan Drug, RMAT, Breakthrough Therapy), and agency meeting preparation. Services are delivered through fractional regulatory leadership, project-based consulting, and end-to-end regulatory operations support.
  2. Fractional Regulatory Leadership: Provides senior-level regulatory leadership (Fractional Head of Regulatory) to biotech companies without full-time hiring needs. This subscription-style engagement model offers flexible, ongoing regulatory guidance and execution support, backed by a team of multi-disciplinary specialists.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based professional services engagement

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

RareMoon Consulting product offering

Product offering

Core offering

RareMoon Consulting provides regulatory affairs consulting services for life science and rare disease companies developing orphan drugs and advanced therapies. Its core offerings include fractional regulatory leadership, regulatory strategy, FDA/EMA/global submissions (IND, CTA, NDA, BLA), orphan drug and expedited program designations (RMAT, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, PRIME), health agency meeting support, and end-to-end regulatory operations and publishing. All services are delivered through expert consulting engagements rather than a software platform.

Product overview

RareMoon Consulting is a regulatory services firm offering a comprehensive portfolio of consulting services for life science and rare disease companies. The core offering centers on regulatory affairs expertise for small molecules, biologics, and advanced therapeutic products including cell and gene therapies. Key services include Fractional Regulatory Services (senior regulatory leadership), Gene Therapy Consulting, Regulatory Filings & Operations (IND/CTA/BLA/NDA submissions), Orphan Drug Designations, Regulatory Designations (RMAT, Breakthrough Therapy, Fast Track, PRIME), Health Agency Meetings, and Publishing & Submissions. The firm provides end-to-end support across FDA, EMA, Health Canada, and global health agencies, with specialized expertise in FDA Rare Pediatric Disease designations. RareMoon does not offer a software platform or technology product; all services are delivered through expert consulting engagements.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fractional Regulatory Services Provides senior-level regulatory leadership and real-time regulatory advisement to biotech and pharmaceutical sponsors developing orphan drugs and advanced therapies without the cost of full-time hires.
  • Gene Therapy Consulting Regulatory and development strategy for cell and gene therapy programs, including AAV, CAR-T, CRISPR, epigenetic platforms, and other regenerative medicine products.
  • Regulatory Filings & Operations Strategic preparation and execution of IND, CTA, NDA, BLA, and global regulatory submissions to FDA, EMA, Health Canada, and EU national agencies.
  • Orphan Drug Designations End-to-end support for securing FDA and EMA Orphan Drug Designations, including eligibility assessment, authoring, quality review, and submission management.
  • Regulatory Designations Strategic support for expedited FDA and EMA designations including RMAT, Breakthrough Therapy, Fast Track, Priority Review, Rare Pediatric Disease, and PRIME, including eligibility, authoring, submission, and post-designation planning.
  • Health Agency Meetings End-to-end support for FDA, EMA, Health Canada, and global health agency meetings including INTERACT, Pre-IND, End-of-Phase, and Scientific Advice sessions.
  • Publishing & Submissions End-to-end regulatory publishing and submission management including eCTD formatting, quality control, regulatory project management, SME applications for EMA, and US Agent/EU Sponsor services.

Quantifiable outcome

  • 100% RMAT success rate since supporting the first RMAT ever granted by FDA in 2017
  • +4 more outcomes

Companies that use RareMoon Consulting

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

RareMoon Consulting technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

RareMoon Consulting partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Franklin BiolabscoreStrategic or Co-development Partner · 7 May 2026RareMoon Consulting and Franklin Biolabs announced a strategic partnership in May 2026 to offer integrated consulting packages supporting preclinical-to-clinical development transitions. Franklin Biolabs is a preclinical contract research organization specializing in genetic medicine and biologics. The collaboration aims to help sponsors design development programs that align with regulatory expectations, reduce development risk, prevent delays, and accelerate timelines by avoiding unnecessary studies. Both companies will discuss the partnership at the ASGCT Annual Meeting in Boston, May 12-14, 2026.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

RareMoon Consulting competitors and assessment

Company assessment

Direct peers

  • ProPharma Group: Regulatory, compliance, and medical affairs consulting firm serving pharma, biotech, and medical device clients. Comparable to RareMoon in providing regulatory strategy and submission support, with broader compliance offerings.
  • NDA Group: Regulatory and HTA consulting firm with strong FDA and EMA capabilities serving pharma and biotech clients. Comparable to RareMoon's transatlantic regulatory practice and orphan drug expertise.
  • Halloran Consulting Group: Regulatory and quality consulting firm serving life sciences companies across development phases. Comparable to RareMoon in offering regulatory strategy, submissions support, and quality services to biotech and pharma sponsors.
  • Biologics Consulting Group: Regulatory consulting firm specializing in biologics, vaccines, and advanced therapies with deep FDA CBER expertise. Closely comparable to RareMoon's advanced therapy and gene therapy consulting practice.
  • Bionical Emas: Regulatory and medical affairs consultancy serving biotech and pharma with expertise across rare disease and advanced therapies. Comparable to RareMoon in regulatory strategy and orphan drug submissions support.
  • Camargo Pharmaceutical Services: Specialized regulatory consulting firm with deep orphan drug, 505(b)(2), and complex generics expertise. Highly comparable to RareMoon as a niche consultancy serving small and mid-cap pharma sponsors on regulatory strategy and FDA interactions.
  • Voisin Consulting Life Sciences (VCLS): Global regulatory and HTA consulting firm serving biotech and pharma with FDA, EMA, and international submission expertise. Comparable to RareMoon in regulatory strategy and orphan drug focus, with a broader global footprint.

Broad incumbents

  • IQVIA: World's largest CRO with extensive regulatory consulting capabilities spanning small molecules, biologics, and advanced therapies. Represents scale competition to boutique regulatory consultancies like RareMoon.
  • Parexel International: Large global CRO offering regulatory consulting, clinical development, and commercialization services across all therapeutic areas. Represents the broad incumbent alternative to boutique firms like RareMoon, with bundled service offerings.
  • PharmaLex (a Cencora company): Global regulatory and pharmacovigilance consulting firm now part of Cencora, offering FDA, EMA, and global submission services. Comparable to RareMoon in regulatory strategy with much broader geographic and therapeutic coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

RareMoon Consulting social profiles

Digital presence

RareMoon Consulting financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RareMoon Consulting leadership team

Management profile

Number of profiles

Profiles9 records

RareMoon Consulting funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RareMoon Consulting M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RareMoon Consulting

What does RareMoon Consulting do?

RareMoon Consulting provides regulatory affairs consulting services for life science and rare disease companies developing orphan drugs and advanced therapies. Its core offerings include fractional regulatory leadership, regulatory strategy, FDA/EMA/global submissions (IND, CTA, NDA, BLA), orphan drug and expedited program designations (RMAT, Breakthrough Therapy, Fast Track, Rare Pediatric Disease, PRIME), health agency meeting support, and end-to-end regulatory operations and publishing. All services are delivered through expert consulting engagements rather than a software platform.

Is RareMoon Consulting a public or private company?

RareMoon Consulting is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RareMoon Consulting founded?

RareMoon Consulting was founded in 2016. It employs 1 to 10 people.

Where is RareMoon Consulting based?

RareMoon Consulting is headquartered in Baltimore, United States, in the North America region.

How does RareMoon Consulting make money?

Two revenue lines are on record. Regulatory Consulting Services are the primary driver. The others are fractional Regulatory Leadership.

Who are RareMoon Consulting's main competitors?

Direct peers on record are ProPharma Group, NDA Group, Halloran Consulting Group, Biologics Consulting Group, Bionical Emas, Camargo Pharmaceutical Services and Voisin Consulting Life Sciences (VCLS). Broad incumbents are IQVIA, Parexel International and PharmaLex (a Cencora company).

Does RareMoon Consulting have an API?

No public API is recorded for RareMoon Consulting.

What industry is RareMoon Consulting in?

RareMoon Consulting's product category is Pharmaceutical Regulatory Affairs Consulting. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541618 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournFranklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory ExpertiseFranklin Biolabs, a preclinical contract research organization specializing in genetic medicine and biologics, and RareMoon Consulting, a regulatory services firm focused on orphan drugs and advanced therapies, have announced a strategic partnership to offer joint consulting packages for preclinical-to-clinical transitions. The collaboration aims to help sponsors design development programs that align with regulatory expectations, reduce development risk, prevent delays, and accelerate timelines by avoiding unnecessary studies. Both companies will discuss the partnership at the ASGCT Annual Meeting in Boston, May 12–14.PR NewswireFranklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory ExpertiseFranklin Biolabs, a preclinical contract research organization specializing in genetic medicines and biologics, and RareMoon Consulting, a regulatory services firm focused on orphan drugs and advanced therapies, have announced a strategic partnership to offer integrated consulting packages supporting preclinical-to-clinical development transitions. The collaboration aims to help sponsors reduce development risk, prevent delays, and accelerate timelines by designing regulatory-aligned development programs that focus on meeting regulatory expectations. Both companies will attend the ASGCT Annual Meeting in Boston, Massachusetts from May 12–14, 2026.